+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07323654

Randomized Study of Oral KT-621 for Adults With Uncontrolled Moderate to Severe Eosinophilic Asthma Evaluating Safety and Efficacy

Led by Kymera Therapeutics, Inc. · Updated on 2026-10-06

264

Participants Needed

81

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.

CONDITIONS

Brief Title

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Research Team

K

Kymera Medical Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here